Chlamydia trachomatis Serology in Women with and without Ovarian Cancer

Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer (n = 521) and population-based controls (n = 766) were tested....

Descripción completa

Detalles Bibliográficos
Autores principales: Ness, Roberta B., Shen, Caixia, Bass, Debra, Jackson, Carlynn, Moysich, Kristen, Edwards, Robert, Brunham, Robert C.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605844/
https://www.ncbi.nlm.nih.gov/pubmed/19125176
http://dx.doi.org/10.1155/2008/219672
Descripción
Sumario:Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer (n = 521) and population-based controls (n = 766) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (≥0.40 OD units) were 0.6 (95% CI 0.4–0.9). These data do not support our earlier finding of elevated titers for antibodies to C. trachomatis among women with ovarian cancer.

Ejemplares similares